# Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

> **NCT00325650** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 2420 (actual)

## Conditions studied

- Prediabetic State

## Interventions

- **DRUG:** Rimonabant
- **DRUG:** Placebo (for Rimonabant)

## Key facts

- **NCT ID:** NCT00325650
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 2420 (ACTUAL)
- **Why stopped:** Company decision taken in light of demands by certain national health authorities
- **Last updated:** 2016-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325650, "Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00325650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*